Evidence map›Paper›PMID 37709748›Full record

ArticleTranslational psychiatry2023

Behavioral and neurocognitive factors distinguishing post-traumatic stress comorbidity in substance use disorders.

David C Houghton, Heidi M Spratt, Lori Keyser-Marcus, James M Bjork, Gretchen N Neigh, Kathryn A Cunningham, Tatiana Ramey, F Gerard Moeller

Abstract read
In one paragraph

Article in Translational psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Post-traumatic stress comorbidity in substance use disorder: machine learning analyses of phenotypic drivers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

David C Houghton *Center for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, TX, USA. dahought@utmb.edu.ORCID http://orcid.org/0000-0003-1443-4179
Heidi M Spratt *Center for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, TX, USA.
Lori Keyser-MarcusInstitute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA.
James M BjorkInstitute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0003-0593-3291
Gretchen N NeighDepartment of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond, VA, USA.ORCID http://orcid.org/0000-0003-0955-9161
Kathryn A CunninghamCenter for Addiction Sciences and Therapeutics, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-4257-1739
Tatiana RameyDivision of Therapeutics and Medical Consequences, National Institute of Drug Abuse, National Institutes of Health, Rockville, MD, USA.
F Gerard MoellerInstitute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA.

Funding

Preclinical Assessment of Compounds for Cocaine Use Disorder (CocUD)U54DA038999 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2014 to 2018
$6.8M
UTMB Clinical and Translational Science AwardKL2TR001441 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI AMEREDES, BILL T · 2015 to 2024
$4.0M
NCATS NIH HHS KL2 TR001441NIDA NIH HHS U54 DA038999
6 · The paper itself

Abstract

Significant trauma histories and post-traumatic stress disorder (PTSD) are common in persons with substance use disorders (SUD) and often associate with increased SUD severity and poorer response to SUD treatment. As such, this sub-population has been associated with unique risk factors and treatment needs. Understanding the distinct etiological profile of persons with co-occurring SUD and PTSD is therefore crucial for advancing our knowledge of underlying mechanisms and the development of precision treatments. To this end, we employed supervised machine learning algorithms to interrogate the responses of 160 participants with SUD on the multidimensional NIDA Phenotyping Assessment Battery. Significant PTSD symptomatology was correctly predicted in 75% of participants (sensitivity: 80%; specificity: 72.22%) using a classification-based model based on anxiety and depressive symptoms, perseverative thinking styles, and interoceptive awareness. A regression-based machine learning model also utilized similar predictors, but failed to accurately predict severity of PTSD symptoms. These data indicate that even in a population already characterized by elevated negative affect (individuals with SUD), especially severe negative affect was predictive of PTSD symptomatology. In a follow-up analysis of a subset of 102 participants who also completed neurocognitive tasks, comorbidity status was correctly predicted in 86.67% of participants (sensitivity: 91.67%; specificity: 66.67%) based on depressive symptoms and fear-related attentional bias. However, a regression-based analysis did not identify fear-related attentional bias as a splitting factor, but instead split and categorized the sample based on indices of aggression, metacognition, distress tolerance, and interoceptive awareness. These data indicate that within a population of individuals with SUD, aberrations in tolerating and regulating aversive internal experiences may also characterize those with significant trauma histories, akin to findings in persons with anxiety without SUD. The results also highlight the need for further research on PTSD-SUD comorbidity that includes additional comparison groups (i.e., persons with only PTSD), captures additional comorbid diagnoses that may influence the PTSD-SUD relationship, examines additional types of SUDs (e.g., alcohol use disorder), and differentiates between subtypes of PTSD.

Indexed as

Stress Disorders, Post-TraumaticSubstance-Related DisordersAggressionAnxietyComorbidityHumans

Identifiers

PMID37709748
PMCPMC10502088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.